Pipilis A, Flather M, Collins R, Hargreaves A, Kolettis T, Boon N, Foster C, Appleby P, Sleight P
Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford.
Br Heart J. 1993 Feb;69(2):161-5. doi: 10.1136/hrt.69.2.161.
To assess the effects of oral vasodilator treatment on ventricular arrhythmias in acute myocardial infarction.
Coronary care units at the John Radcliffe Hospital, Oxford, and the Royal Infirmary, Edinburgh.
100 patients with suspected acute myocardial infarction entered the study at a mean of 13 hours from symptom onset. DESIGN OF INTERVENTION: Double blind randomisation to 4 weeks treatment with captopril (12.5 mg three times a day after a 6.25 mg test dose (n = 32)) or isosorbide mononitrate (20 mg three times a day (n = 31)) or placebo control (n = 37).
Ventricular arrhythmic events assessed by 48 hours of Holter monitoring starting at the time of randomisation.
The number of ventricular extrasystoles/hour for captopril, mononitrate, and placebo was respectively (median and range) 6 (0-162), 4 (0-38), and 10 (0-932) (2p < 0.02 mononitrate v placebo). The number of episodes of multiple extrasystoles/hour was 0.2 (0-22), 0.3 (0-4), and 0.5 (0-19); (2p < 0.02 mononitrate v placebo). Episodes of ventricular tachycardia showed a non-significant decrease in the captopril and mononitrate groups (mean (SEM) 3.2 (0.8), 2.4 (0.7), and 4.7 (1.3) for the 48 hour period). The incidence of idioventricular rhythm was also reduced in both active treatment groups (28%, 19%, and 46% (2p < 0.05 mononitrate v placebo)).
Oral mononitrate (and perhaps also captopril) seems to reduce the incidence of ventricular arrhythmias in the early phase of acute myocardial infarction. The effects on life-threatening arrhythmias, such as ventricular fibrillation, and on death can only be assessed in a much larger trial.
评估口服血管扩张剂治疗对急性心肌梗死患者室性心律失常的影响。
牛津约翰拉德克利夫医院和爱丁堡皇家医院的冠心病监护病房。
100例疑似急性心肌梗死患者在症状发作平均13小时后进入研究。
双盲随机分组,分别接受卡托普利(试验剂量6.25mg后,12.5mg每日三次,共4周,n = 32)、单硝酸异山梨酯(20mg每日三次,共4周,n = 31)或安慰剂对照(n = 37)治疗。
从随机分组时开始进行48小时动态心电图监测,评估室性心律失常事件。
卡托普利组、单硝酸异山梨酯组和安慰剂组每小时室性早搏数量分别为(中位数及范围)6(0 - 162)、4(0 - 38)和10(0 - 932)(单硝酸异山梨酯组与安慰剂组比较,P < 0.02)。每小时多源性早搏发作次数分别为0.2(0 - 22)、0.3(0 - 4)和0.5(0 - 19);(单硝酸异山梨酯组与安慰剂组比较,P < 0.02)。室性心动过速发作次数在卡托普利组和单硝酸异山梨酯组有非显著性下降(48小时期间,平均值(标准误)分别为3.2(0.8)、2.4(0.7)和4.7(1.3))。两个活性治疗组的室性自主心律发生率也降低(分别为28%、19%和46%(单硝酸异山梨酯组与安慰剂组比较,P < 0.05))。
口服单硝酸异山梨酯(可能还有卡托普利)似乎可降低急性心肌梗死早期室性心律失常的发生率。对危及生命的心律失常如室颤以及对死亡的影响只能在更大规模的试验中进行评估。